Related Experiment Videos
[Clinical application of a sustained release anticancer pellet]
No Shinkei Geka. Neurological Surgery
|December 1, 1985
Summary
This study evaluated sustained-release anticancer pellets for brain tumors. The treatment showed limited efficacy for tumors located more than 5 cm from the pellets.
Area of Science:
- Neuro-oncology
- Pharmacology
- Biomedical Engineering
Context:
- Brain tumors, including gliomas and metastatic lesions, pose significant treatment challenges.
- Surgical intervention and radiotherapy are standard treatments, often supplemented with chemotherapy.
- Novel drug delivery systems are being explored to improve therapeutic outcomes.
Purpose:
- To assess the efficacy of sustained-release anticancer pellets in treating various brain tumors.
- To evaluate the survival rates and tumor response in patients receiving this localized chemotherapy.
- To determine the effective range of this drug delivery method.
Summary:
- 136 patients with gliomas, metastatic brain tumors, or benign astrocytomas received sustained-release anticancer pellets combined with standard therapies.
- Anticancer agents (5FU, MMC, BUdR, urokinase) were delivered via Silastic silicone tubes.
- Median survival times varied by tumor type, with limited efficacy observed for tumors >5 cm from the pellets.
Impact:
- The study highlights the limitations of localized sustained-release chemotherapy for distant brain tumors.
- Findings suggest that the effective therapeutic range of these pellets is restricted.
- This research informs the development of more effective localized treatment strategies for brain malignancies.